Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Nivolumab Re-challenge in Advanced NSCLC After Prior PD-1/PD-L1 Inhibitor Benefit (WJOG9616L)
jRCTs051180019Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoint: objective response rate. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180019.